Interesting investor perspective. Thoughts? http://seekingalpha.com/article/1676502-pfizer-looks-good-despite-disappointing-eliquis-sales?source=email_rt_article_readmore
3rd to market. Confusion over superiority endpoints. Tough upsell. This drug needs managed care pull-through support as step-therapy, 1st choice. Pfizer needs to rebate this product to get share uptake.
CIA cut the balls off Pfizer sales force. Legal rules and they don't want the sales force to sell. They want the sales force to record compliant activities.
That the "analyst" has no friggin' idea what he's talking about. Apixaban has one US indication and is no better than any of the noval orals.
Consensus estimates have been falling for BMY's Eliquis: http://bit.ly/1aTLT6J Check the chart out at the bottom where you can compare broker forecasts to a quarter ago / year ago. Eqliuis estimates have fallen from >$4bn to$2.7bn
Re: Pfizer Looks Good Despite Disappointing Eliquis Sales That's like saying she looks fine if it wasn't for that Thyroid Goiter that looks like a couple of testicles implanted inside her face!
Don't worry IS will come in and save the day. Just look what we've done with Prevnar. Will add at least 1 mill to the bottom line. We ARE the premier sales force in Pfizer!!! Accept It. Own It.